Peer-influenced content. Sources you trust. No registration required. This is HCN.

MedPage TodayNeodjuvant Chemoimmunotherapy Takes Another Step Forward in Stage IIIA-B NSCLC

At 12 months, nivolumab plus chemotherapy yielded a PFS of 89.3% versus 60.7% for
chemotherapy alone and an OS of 98.2% compared with 82.1%, respectively. The
combination improved median PFS by 52% compared with chemotherapy alone at a
median follow-up of 26.1 months. (See also NADIM II and IMpower010 Provide Support for Neoadjuvant and Adjuvant Immunotherapy in Lung Cancer)

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form